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Abstract
Remyelination is in the center of new therapies for the treatment of multiple sclerosis to resolve
and improve disease symptoms and protect axons from further damage. Although remyelination is
considered beneficial in the long term, it is not known, whether this is also the case early in lesion
formation. Additionally, the precise timing of acute axonal damage and remyelination has not been
assessed so far. To shed light onto the interrelation between axons and the myelin sheath during
de- and remyelination, we employed cuprizone- and focal lysolecithin-induced demyelination and
performed time course experiments assessing the evolution of early and late stage remyelination
and axonal damage. We observed damaged axons with signs of remyelination after cuprizone diet
cessation and lysolecithin injection. Similar observations were made in early multiple sclerosis
lesions. To assess the correlation of remyelination and axonal damage in multiple sclerosis lesions,
we took advantage of a cohort of patients with early and late stage remyelinated lesions and
assessed the number of APP- and SMI32- positive damaged axons and the density of SMI31-
positive and silver impregnated preserved axons. Early de- and remyelinating lesions did not differ
with respect to axonal density and axonal damage, but we observed a lower axonal density in late
stage demyelinated multiple sclerosis lesions than in remyelinated multiple sclerosis lesions. Our
findings suggest that remyelination may not only be protective over a long period of time, but may
play an important role in the immediate axonal recuperation after a demyelinating insult.
K E YWORD S
axonal damage, multiple sclerosis, remyelination
1 | INTRODUCTION
Persistent disability and disease progression in multiple sclerosis are
tightly connected to neuro-axonal damage and loss (Simons, Misgeld, &
Kerschensteiner, 2014; Singh et al., 2017). Disturbances of axonal trans-
port and metabolism, often visualized by immunohistochemistry for axo-
nally transported proteins, such as amyloid precursor protein (APP) or
SMI32, a marker for dephosphorylated neurofilaments of damaged
axons, are most abundant in early stages of lesion formation and, accord-
ing to experimental data, only a proportion of these damaged axons will
undergo axonal transection (Sorbara et al., 2014; Nikic et al., 2011; Trapp
et al., 1998). A number of inflammatory mediators have been accused to
impair axonal function, mainly derived from phagocytes actively stripping
off the myelin sheaths in early lesions (Clark et al., 2016; Cunningham,
2013; Lassmann, 2014). Experimentally, NO and ROS, highly reactive
lipid soluble mediators, are responsible for an important share of the
acute axonal damage observed (Nikic et al., 2011; Sorbara et al., 2014).
Abbreviations: APP, amyloid precursor protein; EAE, experimental
autoimmune encephalomyelitis; NO,, nitric oxide; ROS, reactive oxygen
species.
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In addition to therapeutically addressing the plethora of inflammatory
mediators present, remyelination of axons is considered as one of the
most important endogenous axon-protective mechanisms. Aside from
restoring the conductive properties of the axon, remyelination provides
insulation of the axon against a potentially hostile microenvironment and
restores the close metabolic interaction with oligodendrocytes
(F€unfschilling et al., 2012; Lee et al., 2012; Morrison et al., 2015). The
correlation of early remyelination and axonal damage and whether dam-
aged axons can be remyelinated, is unknown so far.
To study the interrelation between demyelination, remyelination,
and axonal damage in detail, we employed the mouse model of
cuprizone-induced demyelination and focal lysolecithin-induced demy-
elination and performed tight time course experiments assessing the
evolution of remyelination and acute axonal damage. We found that
the density of APP-positive axons gradually declined after removing
cuprizone from the diet and during the phase of lesion repair after lyso-
lecithin injection, indicating an overall beneficial role of remyelination.
In addition, APP-positive axonal profiles enwrapped by myelin sheaths
were found in early remyelinating multiple sclerosis lesions as well as
during remyelination in our experimental models. In the present work,
we took also advantage of a cohort of patients with early and late
stage remyelinated lesions and assessed the density of damaged and
preserved axons. No significant difference in the density of preserved
and damaged axons could be observed between remyelinating and
demyelinating multiple sclerosis lesions early in lesion formation. How-
ever, we could demonstrate that in late stage disease, the amount of
preserved axons was significantly higher in remyelinated than in
demyelinated multiple sclerosis lesions.
Our findings suggest that the re-establishment of a myelin sheath
does not depend on a functional axonal transport and intact axonal
metabolism and might even aid the recuperation of damaged axons.
Thus, our data support a protective role of remyelination in early as
well as late stage lesion development.
2 | MATERIALS AND METHODS
2.1 | Multiple sclerosis tissue
In this study formalin-fixed and paraffin-embedded biopsy and autopsy
CNS tissue of patients with multiple sclerosis was used, which was col-
lected at the Institute of Neuropathology at the University Medical
Centre G€ottingen (Supplementary Table 1 and 2). Lesions were
assessed by A.J. and C.S. according to criteria described elsewhere
(Br€uck et al., 1994, 1995; Kutzelnigg et al., 2005; Lassmann, 2011; Luc-
chinetti et al., 2000; Schuh et al., 2014). The study was performed in
accordance with national and local ethics regulations and approved by
the UMG ethics committee.
2.1 | Animals
For all in vivo experiments 6 to 7-week-old male C57BL/6J mice and
adult female Lewis rats (200–220 g) were purchased from Charles
River (Sulzfeld, Germany). Up to 6 animals were housed together on a
12/12 h light/dark cycle and had access to food and water ad libitum.
Animal experiments were conducted in accordance with the European
Communities Council Directive of November 24th, 1986 (86/EEC) and
were approved by the Government of Lower Saxony, Germany.
2.3 | Cuprizone mouse model
About 7 to 8-week-old male C57BL/6J mice were fed for 6 weeks
with the cupper chelator cuprizone (0.25% in normal chow) to induce
demyelination in the brain. After cuprizone withdrawal mice were fed
with normal diet to analyze remyelination. During de- and remyelina-
tion, that is after 6 weeks of cuprizone treatment and 2, 3, 4, 5, 6, 7,
14 and 21 days after cuprizone diet cessation, brains of mice were har-
vested and processed for analysis by histochemistry and immunohisto-
chemistry. Untreated, age-matched mice were used as a control.
Mouse brain tissue was fixed with 4% paraformaldehyde (PFA) and
embedded into paraffin. For histological evaluation 1 mm coronal sec-
tions were used.
2.4 | Focal lysolecithin-induced demyelination
Adult Lewis rats (200–220 g) were anaesthetized by intraperitoneal
injection of ketamine/xylazine. The scalp was opened and the animal
was mounted on a stereotactic device. A small hole (Ø 2 mm) was
drilled 2 mm lateral and 1 mm caudal to the bregma. One ml of 0.5%
lysolecithin (Sigma-Aldrich) diluted in sterile PBS was slowly (3 min)
injected into the corpus callosum (2.5 mm depth) using a fine calibrated
glass capillary. Afterwards the capillary was removed and the skin was
sutured. Animals were perfused 3, 6, 12, and 20 days postinjection for
histochemical and immunohistochemical analysis.
2.5 | Histology
Bielschowsky silver impregnation and Luxol fast blue periodic acid
Schiff (LFB-PAS) staining were performed according to standard proce-
dures. Primary antibodies utilized for immunohistochemistry were
against injured axons (APP, 1:2,000, clone 22C11, Chemicon) and non-
phosphorylated neurofilaments (SMI32, 1:1,000, Covance, Princeton,
NJ, USA), healthy phosphorylated neurofilaments/axons (SMI31,
1:10,000, Covance, Princeton, NJ, USA), myelin basic protein (MBP,
1:2,000, Dako), activated microglia (Mac3, also known as Lamp2,
1:200, clone M3/84, BD Pharmingen), glial fibrillary acidic protein
(GFAP, 1:1,000, Dako), and foamy monocytes and macrophages
(CD68, 1:5,000, clone KiM1P). Biotinylated secondary antibodies (GE
Healthcare, Jackson ImmunoResearch and DCS Innovative diagnostic
system), peroxidase conjugated avidin and DAB (Sigma-Aldrich) were
used for immunohistochemistry. Fluorescence labeled secondary anti-
bodies (Cy3-conjugated goat anti-mouse IgG, 1:200, Jackson Immu-
noResearch and Alexa488-conjugated goat anti-rabbit IgG, 1:200,
Molecular Probes, Life technologies) were used for fluorescence
immunohistochemistry.
2.6 | Morphometry and data acquisition
The level of demyelination of the corpus callosum after cuprizone
treatment was assessed in LFB-PAS stained and MBP immunostained
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sections by a semi-quantitative score: no demyelination (0), 0–33%
demyelination (1), 33%–66% demyelination (2), and more than 66%
demyelination (3) (Hiremath et al., 1998). APP1 and SMI321 axons and
the number of glial cells and infiltrating phagocytes (Mac31, KiM1P1,
GFAP1 cells) were determined in the corpus callosum or in the lesion
area at 4003 with an ocular counting grid (light microscope BX41 and
ocular counting grid WHSZ 10X-H, both Olympus). To evaluate acute
axonal damage in the context of early remyelination, fluorescence dou-
ble immunohistochemistry (APP and MBP) was analyzed by confocal
microscopy (laser scanning confocal microscope FluoView FV1000
(Olympus)). Therefore, 30 randomly selected visual fields with at least
one APP1 axon were measured per corpus callosum at 400x with 7%
zoom. The degree of association of APP with MBP (myelinated APP1
axons) was assessed by a qualitative evaluation using the software
FV10-ASW 4.0 viewer. The data were calculated as percent of all
assessed APP1 axons per corpus callosum.
The acute axonal damage in early stage demyelinating and remyeli-
nating multiple sclerosis lesions was evaluated by fluorescence double
immunohistochemistry (APP or SMI32 with MBP) and confocal micros-
copy. For qualitative analysis, 10 randomly selected visual fields with at
least one APP1 spheroid were analyzed.
Axonal density within the lesions was determined in sections
stained with SMI31 and Bielschowsky silver impregnation by using an
axonal counting grid with 25 cross-points at a magnification of 10003
under oil immersion. The number of axons that crossed a grid line was
counted as a fraction of the total number of cross-points. The number
of axons crossing the points in normal appearing white matter was set
to 100%. The degree of axon reduction in the lesion is given as the per-
centage of axon density compared with normal appearing white matter.
2.7 | Imaging
All images were acquired using either the Fluorescence microscope
BX51 (Olympus) and Camera DP71/XM10 (Olympus) or the Laser
scanning confocal microscope FluoView FV1000 (Olympus). They are
presented as captured; only white balance was applied to light micro-
scopical images.
2.8 | Statistical analysis
Statistics were calculated using the GraphPad Prism 5.01 software. The
Kolmogorov–Smirnov test was carried out to test the data for normal
distribution. To compare more than two groups, data were analyzed by
one-way ANOVA for parametric data (Bonferroni’s Multiple Compari-
son test). For analysis of nonparametric data the Kruskal-Wallis test
was used (Dunn’s Multiple Comparison test). For comparison of two
groups the paired or unpaired t test was used for parametric data and
the Mann-Whitney test was used for nonparametric data. A p-value of
<0.05 was considered as statistically significant.
3 | RESULTS
3.1 | Newly remyelinated axons were accompanied by
diminished axonal damage in the presence of
microglial activation in the cuprizone mouse model
To elucidate the occurrence of axonal damage over time during the for-
mation of new myelin sheaths, we performed tight time course experi-
ments in the cuprizone mouse model, an animal model for de- and
remyelination (Figure 1).
To determine the time course of remyelination the content of
myelin was analyzed by histochemistry and immunohistochemistry.
LFB-PAS histochemistry and myelin basic protein immunoreactivity
revealed an almost complete demyelination of the corpus callosum
after 6 weeks of cuprizone treatment (Figure 2a–c). Significant remyeli-
nation was observed 4 days after diet cessation. After 1 week of cupri-
zone withdrawal a major proportion of the corpus callosum was
remyelinated, which was almost completed after 3 weeks of recovery
(Figure 2b, c).
To investigate the interrelationship of newly formed myelin and
acute axonal damage, immunohistochemistry for APP was performed.
APP is undetectable in healthy axons, but accumulates in injured axons
with disturbed anterograde axonal transport. APP immunohistochemis-
try revealed swollen axons and axonal spheroids after 6 weeks of
cuprizone treatment (median 309.1 APP1 axons/mm2) and during early
(2 days, median 229.5 APP1 axons/mm2) and long standing (3 weeks,
median 129.2 APP1 axons/mm2) remyelination. The number of APP1
axons decreased gradually during remyelination, with a significant dif-
ference at day 6 after diet cessation compared with 6 weeks of demye-
lination (cuprizone feeding), and a few were still present after 3 weeks
of recovery (Figure 2a, d).
To assess whether the axons experienced damage because of
demyelination, the activation of microglia or the reactivation of astro-
cytes, we determined the microgliosis and astrogliosis by
FIGURE 1 Design of the cuprizone experiments to investigate the timing and relation of acute axonal damage and remyelination. 7 to 8-
week-old male C57BL/6J mice were fed for 6 weeks with a 0.25% cuprizone diet to induce demyelination in the corpus callosum.
Demyelinated lesions remyelinate after cuprizone withdrawal. To study early and late remyelination, CNS tissue was harvested from days 2
to 7, and on days 14 and 21 after cuprizone diet cessation
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FIGURE 2 Comprehensive assessment of white matter pathology early and late after cuprizone-induced demyelination. (a) Representative
images of the medial corpus callosum of control mice and mice after cuprizone challenge for 6 weeks and after 4 days of recovery. Myelin
assessment by LFB-PAS histochemistry and MBP immunohistochemistry (IHC) indicated an almost complete demyelination of the corpus
callosum after 6 weeks of cuprizone feeding. Significant remyelination was observed 4 days after diet cessation. Acute axonal damage
(APP1 axons) decreased during remyelination in the cuprizone model. Microglial cells were activated during demyelination. The number of
Mac31 activated microglia declined during remyelination in comparison to 6 weeks of demyelination, while the density of reactive astro-
cytes (GFAP1 cells) did not change during the period of remyelination observed here. (b, c) The demyelinated area in the corpus callosum
was reduced during remyelination as judged by semi-quantitative evaluation of LFB-PAS and MBP IHC. The demyelinated area was signifi-
cantly reduced after 4 and 7 days (*p<0.05; **p<0.01; n55-17; mean6 SEM). (d) Acute axonal damage was observed after cuprizone-
induced demyelination in the corpus callosum and was decreased already after 2 days of recovery. The density of APP1 axons decreased
continuously during remyelination (*p<0.05; ***p<0.001; n55-17; median). (e) Three days after cuprizone withdrawal the number of acti-
vated microglia was significantly diminished and almost absent after 3 weeks of remyelination (***p<0.001; n55-17; mean6 SEM). (f) The
evaluation of immunoreactivity for GFAP revealed a persistent activation of astrocytes. (g) The activation of microglia correlated with the
amount of damaged axons during recovery after cuprizone diet ingestion (p5 0.0028; R25 0.7981; n58; mean)
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immunoreactivity for GFAP and Mac3. Many activated microglia
(975.9656.5 cells/mm2) and reactive astrocytes (629.3627.4 cells/
mm2) were present after 6 weeks of cuprizone treatment (Figure 2a, e,
and f). The number of Mac31 cells was significantly diminished 2 days
after cuprizone withdrawal. Mac31 cells were almost absent after 3
weeks of recovery (26.7669.9 cells/mm2) (Figure 2a, e). Immunohisto-
chemistry for GFAP displayed a high number of reactive astrocytes in
the demyelinated and remyelinated corpus callosum (3 weeks recovery:
478.0631.07 cells/mm2) (Figure 2a, f). Thus, the number of acutely
damaged axons decreased during early remyelination in the presence
of diminishing microglial activation. Microglial activation was found to
strongly correlate with axonal damage, and thus may play a role in its
formation (R25 0.7981, p50.0028) (Figure 2g).
3.2 | Axons with disturbed axonal transport were
remyelinated after cuprizone withdrawal and after
lysolecithin-induced demyelination
Nikic and colleagues reported that axonal damage is reversible and
does not lead to axonal degeneration in all cases (Nikic et al., 2011).
To determine whether injured axons can be remyelinated, which
would point to a recuperative role of the newly established myelin
sheath, a comprehensive confocal microscopy investigation was per-
formed. Double immunostaining of APP and MBP revealed two sub-
populations of APP1 axons in the corpus callosum of cuprizone-
treated mice (Figure 3a): unmyelinated and myelinated. The percent-
age of myelinated APP1 axons increased significantly during the first
7 days of recovery (from 6.5% to 25%) (Figure 3b). Because of the
decrease of the amount of acutely damaged axons and the increase
of the number of myelinated, acutely damaged axons over time, it is
highly likely that acutely damaged axons gained a new myelin
sheath, that were remyelinated.
To substantiate that the observation that damaged axons undergo
remyelination during lesion repair is not restricted to the cuprizone
mouse model, we performed focal lysolecithin-induced demyelination in
Lewis rats. In the lysolecithin model, induced by a membrane-dissolving
detergent, axonal damage is important. In contrast to cuprizone-induced
demyelination, lysolecithin-induced lesions are accompanied by recruit-
ment of peripheral immune cells. Spontaneous remyelination starts a
few days after lysolecithin injection. We performed histo- and immuno-
histochemical studies on time course experiments of lysolecithin-
induced lesions. LFB-PAS histochemistry revealed almost completely
demyelinated lesions in the corpus callosum 3 to 6 days after injection,
while almost complete remyelination was seen after 20 days (Figure 4a).
The number of APP1 axons increased during the first 6 days after lyso-
lecithin injection and decreased during the phase of lesion repair, with a
significant difference between days 6 and 20 postinjection (from
30706320.4 to 870.96220.9 APP1 axons/mm2) (Figure 4a, b). Double
labelling with APP and MBP revealed that also in lysolecithin-induced
demyelination, APP-positive axons with transport disturbance become
remyelinated during lesion repair (Figure 5).
3.3 | Myelinated damaged axons were observed in
early stage multiple sclerosis lesions
To verify whether early stage multiple sclerosis lesions exhibit, as seen
in the cuprizone and lysolecithin models, (re)myelinated damaged
axons, a confocal analysis of demyelinating and remyelinating multiple
FIGURE 3 The percentage of myelinated damaged axons increased during remyelination. (a) Unmyelinated and myelinated APP1 axons
were observed in the corpus callosum of mice after demyelination and during remyelination. A representative image of the corpus callosum
3 and 4 days after withdrawal of cuprizone is shown. (b) APP1 axons were analyzed in 30 randomly selected areas with at least one APP1
axon (approx. 50 axons) in the corpus callosum of mice by confocal microscopy. After 1 week of recovery the number of myelinated APP1
axons increased significantly indicating remyelination of damaged axons (**p<0.01; n53-7; mean6 SEM)
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sclerosis lesions was performed. We found nonmyelinated and myelin-
ated injured axons by double immunohistochemistry for APP or SMI32
and MBP in both lesion types (Figure 6a, b). Although more myelinated
APP1 damaged axons were detected in remyelinating lesions, it did not
reach significance (Figure 6c). However, these data support the
hypothesis that damaged axons can be remyelinated after a demyeli-
nating event, which further substantiates the beneficial role of early
remyelination in multiple sclerosis.
FIGURE 4 Significant reduction of acute axonal damage during lesion repair in lysolecithin-induced demyelination.(a) Representative
images of lysolecithin-induced lesions in the rat corpus callosum on days 6 and 20 postinjection. LFB-PAS histochemistry revealed almost
complete demyelination after 6 days and almost complete remyelination after 20 days.APP1 axons were observed in lysolecithin-induced
lesions. (b) The number of APP1 axons in the lesions increased until day 6 and showed a significant decrease on day 20 after lysolecithin
injection (*p<0.05; n53-5; mean6 SD)
FIGURE 5 APP1 axons are remyelinated in lysolecithin-induced lesions.Unmyelinated and myelinated APP1 axons were detected in
lysolecithin-induced lesions during lesion repair. A representative image 12 and 20 days after lysolecithin injection is shown
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3.4 | Characterization of de- and remyelinating and
chronic multiple sclerosis lesions
The MS lesions studied here showed a confluent actively demyelinating
or demyelinated area with or without remyelination. Remyelinated
lesions were characterized by reestablished myelin sheaths, which
appeared less dense, less organized, and thinner than in adjacent normal
appearing white matter in LFB histochemistry (Figure 7a). In addition,
early demyelinating and remyelinating lesions exhibited a prominent
macrophage infiltration with detection of LFB- and MBP-positive myelin
degradation products. In contrast, chronic demyelinated and remyeli-
nated lesions displayed only low numbers of KiM1P1 macrophages that
were devoid of myelin degradation products (Figure 7a, b).
First, we assessed the amount of damaged axons, that is axons
with axonal transport disturbance (APP1 axons and spheroids) and
axons with dephosphorylated neurofilaments (SMI321 axons). Both
were frequently observed in early stage demyelinating as well as
remyelinating lesions (Figure 7a, e, f). We did not find a significant dif-
ference in the extent of axonal damage in demyelinating vs. early
remyelinating lesions and in chronic demyelinated vs. remyelinated
lesions. Second, we asked, whether the overall axonal density differs in
all investigated multiple sclerosis lesions. The axonal density analyzed
in the Bielschowsky silver impregnation and SMI31 immunohistochem-
istry was comparable in demyelinating and remyelinating lesions, while
chronic remyelinated lesions harbored significantly more axons than
chronic demyelinated lesions (Figure 7a, c, d). The overall axonal den-
sity in early stage lesions was lower than in chronic remyelinated
lesions, most likely because of tissue edema and inflammatory cell infil-
tration. In conclusion, our results support a beneficial role of early and
late remyelination.
4 | DISCUSSION
The precise timing of early remyelination in relation to axonal damage
has not yet been studied in detail. In the present study, we performed
tight time course experiments in the cuprizone mouse model and in
focal lysolecithin-induced demyelination. We observed that damaged
axons are able to gain a new myelin sheath, which may act as a “patch”
and may thereby promote axonal recuperation. It has long been
assumed that remyelination is beneficial for axonal preservation in mul-
tiple sclerosis in the long term (Kornek et al., 2000; Kuhlmann, Lingfeld,
Bitsch, Schuchardt, & Br€uck, 2002; Patrikios et al., 2006), which we
confirmed in our study of early and late stage multiple sclerosis lesions.
Hence, our data support the notion that therapies promoting remyeli-
nation would be beneficial at early and late stages of lesion develop-
ment to increase the axonal preservation.
After cuprizone challenge the corpus callosum of mice exhibited
acutely damaged axons, which were identified as APP1 axons or axonal
spheroids. APP1 axonal profiles may reflect axonal transection or
reversible transport disturbance (Nikic et al., 2011). The temporal
sequence of axonal swelling and transection as a consequence of axo-
nal damage and the reversibility of acute axonal damage were recently
studied in EAE by in vivo imaging. This work also showed that APP1
axons in the immediate perilesional area of early lesions were in part
myelinated, suggesting that acute axonal damage may in part occur
FIGURE 6 Myelinated APP1 and SMI321 axons were found in early remyelinating multiple sclerosis lesions. (a, b) Representative
confocal image of myelinated APP1 and SMI321 axons (arrows) in an early remyelinating multiple sclerosis lesion. (c) A higher number of
myelinated axons with axonal transport disturbance were observed in remyelinating compared with demyelinating multiple sclerosis
lesions. This finding suggests that damaged axons in multiple sclerosis lesions are indeed capable of gaining a new myelin sheath (n53,
mean6 SEM)
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FIGURE 7 Less axonal loss in remyelinated multiple sclerosis lesions. (a) LFB-PAS histochemistry shows examples of early (demyelinating
and remyelinating) and late stage (demyelinated and remyelinated) multiple sclerosis lesions. (Re)myelination in the lesions was confirmed
by immunohistochemistry for myelin basic protein (MBP). (b) Early stage lesions exhibited a higher density of KiM1P1 macrophages/acti-
vated microglia compared with late stage lesions. (a, c, d) Axonal loss was observed in all lesion stages with a higher axonal density in
remyelinated multiple sclerosis lesions. (a) APP1 and SMI321 axons reflecting axonal injury were detected in all types of lesions investi-
gated. (e, f) Axonal injury and KiM1P1 macrophages/activated microglia occurred more frequently in early than in late stage multiple sclero-
sis lesions with no significant difference between lesions displaying demyelination and lesions showing remyelination. (c, d) Remyelinated
multiple sclerosis lesions revealed a higher axonal density than early stage lesions and demyelinated lesions (** p<0.01; *** p<0.001;
n53-18; mean6 SD)
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independently of demyelination. In the present study, we observed
that in the cuprizone as well as lysolecithin models, APP1 myelinated
axons increased with lesion repair and remyelination. Thus, remyelina-
tion of damaged axons, as observed here, may be a possibility to facili-
tate axonal recuperation. However, the pathological mechanisms in the
cuprizone model are different from the autoimmune EAE based on
activated encephalitogenic T cells. Only a negligible amount of periph-
eral immune cells infiltrate the corpus callosum of cuprizone treated
mice, while activated and phagocytosing microglia predominate (Hire-
math, Chen, Suzuki, Ting, & Matsushima, 2008; Matsushima & Morell,
2001; Mildner et al., 2007). Therefore, the mechanisms of axonal
pathology and recuperation might differ as well. However, we also
observed remyelination of damaged axons in lysolecithin-induced focal
demyelination, indicating that remyelination of functionally impaired
axons is not restricted to cuprizone-induced demyelination.
In the present study, the number of injured axons decreased con-
tinuously during remyelination in the cuprizone model and also in
lysolecithin-induced demyelination. Remyelination thus seemed to be
axon-protective, and no evidence for heightened vulnerability of axons
during early remyelination was observed in our models (Irvine & Blake-
more, 2006, 2008). In line, previous studies have demonstrated a bene-
ficial effect of remyelination in the cuprizone model by showing
increased axonal damage after remyelination failure induced by oligo-
dendrocyte precursor cell depletion, and decreased axonal damage and
better axonal preservation after induction of remyelination by neuro-
sphere transplantation (Irvine & Blakemore, 2008). Also, restoration of
neurological function could serve as an indicator of increased axon pro-
tection. Along this line, Murray and colleagues reported a partial resto-
ration of neurological functions coinciding with spontaneous
remyelination in a viral model of multiple sclerosis (Murray, McGavern,
Sathornsumetee, & Rodriguez, 2001). Taken together, these results
support an axon-protective role of remyelination substantiating an
important role for therapies that promote remyelination.
For most of the studies exploring mechanisms of demyelination,
remyelination and axonal damage in the cuprizone mouse model, time
intervals of weeks or months were used (Gudi et al., 2009; Lindner,
Fokuhl, Linsmeier, Trebst, & Stangel, 2009; Lindner et al., 2008; Skripu-
letz et al., 2013; Stidworthy, Genoud, Suter, Mantei, & Franklin, 2003).
In the present study the very short time intervals of only days enabled
a detailed analysis of early remyelination and axonal damage. Acute
axonal damage decreased continuously during recovery presumably in
part because of rapid and efficient oligodendrocyte differentiation and
remyelination. However, acute axonal damage (9 APP1 axons/mm2)
was shown to still occur after long-term remyelination (28 weeks)
(Manrique-Hoyos et al., 2012). The axonal damage, which was eval-
uated after one (median 163.3 APP1 axons/mm2) or three (median
129.2 APP1 axons/mm2) weeks of remyelination in the present work,
was much higher than the axonal damage observed in the study of
Manrique-Hoyos and colleagues, indicating that axonal damage is more
prevalent early after cuprizone-diet cessation. Furthermore, damaged
or transected axons could be detected by immunohistochemistry for
APP already a few hours after injury (McKenzie et al., 1996; Otsuka,
Tomonaga, & Ikeda, 1991) and were observed up to four weeks after
the insult (Bramlett, Kraydieh, Green, & Dietrich, 1997; Pierce, Troja-
nowski, Graham, Smith, & McIntosh, 1996). Therefore, the majority of
the axonal damage probably occurred during cuprizone treatment and
demyelination and was still detectable during the phase of
remyelination.
Our study revealed that 25% of APP1 axons appeared myelinated
already after 7 days of remyelination in the cuprizone model. The tem-
poral relation of axonal damage and early remyelination suggests that
axons were efficiently remyelinated independent of their functional
impairment. We could also identify APP1 myelinated axons in
lysolecithin-induced demyelination in the stage of lesion repair. These
data are in line with work on chronically demyelinated axons, which
can still be efficiently remyelinated (Foote & Blakemore, 2005; Mason
et al., 2004). Thus, it was proposed that efficient remyelination
depends rather on the presence of myelinating oligodendrocytes and
specific environmental factors than on the axons themselves. More-
over, a functional axonal transport does not seem to be a necessary
precondition for the establishment of a proper myelin sheath.
We could demonstrate that the number of myelinated injured
axons was increased in early remyelinating multiple sclerosis lesions
compared with demyelinating lesions. This observation suggests that a
similar sequence of events might lead to myelinated damaged axons in
multiple sclerosis. However, the models employed here are devoid of a
significant contribution of adaptive immune cells, and primarily suited
to investigate mechanisms of de- and remyelination. Yet, in multiple
sclerosis, the focal and diffuse immune activation, including adaptive
and innate immune cells, might influence the process of remyelination
and the extent and occurrence of axonal damage.
In conclusion, our work contributes to the elucidation of the mech-
anisms that are important for axonal preservation and remyelination.
The findings of this study demonstrate that axons with functional
impairment, including axonal transport disturbances can still be remyeli-
nated. Remyelination may not only restore saltatory conduction, but
may also actively assist in the preservation of axonal integrity after
axonal damage.
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